What one share of Aprea Therapeutics holds
We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
Aprea Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.60 |
|---|---|
| Cash and investments | $3.33 |
| Book value | $3.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$263.48 | — | — | — | −$620.35 |
| 2018 | — | −$269.04 | $0.06 | −$264.28 | — | −$890.39 |
| 2019 | — | −$93.49 | $0.10 | −$89.10 | — | — |
| 2020 | — | −$50.61 | $0.02 | −$39.58 | — | $73.06 |
| 2021 | — | −$34.88 | — | — | — | $45.30 |
| 2022 | — | −$67.99 | — | — | — | $9.66 |
| 2023 | — | −$3.95 | $0.03 | −$3.39 | — | $4.54 |
| 2024 | — | −$2.35 | $0.00 | −$2.46 | — | $3.52 |
| 2025 | — | −$1.93 | — | — | — | $1.52 |
Common questions about Aprea Therapeutics
How much does one share of Aprea Therapeutics earn?
Over the last 12 months, Aprea Therapeutics lost $0.60 for each share.
Does Aprea Therapeutics pay a dividend?
Aprea Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aprea Therapeutics’s book value per share?
Aprea Therapeutics’s book value is $3.10 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aprea Therapeutics have?
Each share of Aprea Therapeutics has $3.33 of cash and investments, as of June 30, 2026.
Has Aprea Therapeutics bought back shares?
Aprea Therapeutics’s share count rose about 11241% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.